A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Status:
Completed
Trial end date:
2021-08-02
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of 2 dose levels of risankizumab in adult
participants with moderate to severe Hidradenitis Suppurativa (HS). This study includes two
treatment periods. In Period A, participants are randomized to receive either risankizumab
dose A, dose B, or placebo. In Period B, participants who received risankizumab dose A or
placebo during Period A, will receive risankizumab dose B. Participants who received
risankizumab dose B in Period A will remain on that dose in Period B.